GLENMARK

Jan 30 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA Q3 CONSOL NET PROFIT 4.03 BILLION RUPEES

• GLENMARK PHARMA Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 39.01 BILLION RUPEES

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];))

Sept 24 (Reuters) - Jiangsu Hengrui Pharmaceuticals Co Ltd 600276.SS:

• SAYS SIGNS LICENSING AGREEMENT WITH GLENMARK SPECIALTY S.A. FOR PROJECT SHR-A1811

• TO RECEIVE DOWN PAYMENT OF $18 MILLION, MILESTONE PAYMENT OF UP TO $1.1 BILLION

Source text

Further company coverage: 600276.SS

(Reporting by Beijing Newsroom)

(([email protected];))

** Shares of Glenmark Pharma GLEN.NS rise 2.8% to 2,047.3 rupees, their highest in over 3 weeks

** Drugmaker starts phase 3 trial of cancer drug Envafolimab in India after drug regulator's nod

** Company says clinical trial applications are underway in Russia, Brazil, and Mexico

** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG

** Stock up 27.3% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Shares of Glenmark Pharmaceuticals GLEN.NS up 3.5% to 1985 rupees

** HSBC Global Investment Research retains "buy" rating and PT of 2,380 rupees ($27.20) on GLEN on the back of good visibility on growth drivers

** Easing R&D spend, start of supplies from Monroe plant, U.S. FDA approval for gFlovent, pick-up in the U.S. and India businesses led by new launches are key drivers for GLEN's growth - HSBC

** Stock set to rise most in a session since July 11

** Stock has been above its 100-day, 200-day simple moving avgs since June, indicating bullish sentiment

** Avg rating of nine analysts is "buy" and median PT is 2,380 rupees, ~19% higher than current price - data compiled by LSEG

** YTD, GLEN up ~24%

($1 = 87.5060 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Sept 2 (Reuters) - Glenmark Pharmaceuticals GLEN.NS:

• TO LAUNCH ERIBULIN MESYLATE INJECTION IN USA

• TO BEGIN DISTRIBUTION IN SEPTEMBER 2025

Source text: ID:nBSE5B7S0j

Further company coverage: GLEN.NS

(([email protected];))

Aug 19 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC TO LAUNCH MICAFUNGIN FOR INJECTION USP

Source text: ID:nnAZN4DSC95

Further company coverage: GLEN.NS

(([email protected];;))

** Shares of Glenmark Pharma GLEN.NS fall 1.45% to 2,014.9 rupees

** Drugmaker's Q1 consol PBT fell 9% to 4.19 bln rupees ($47.96 million), net sales down by 5% at 30.59 bln rupees hit by pricing pressure in North America and Europe

** Sales in North America slipped 0.4%, while that in Europe dropped 4% for the quarter

** Europe and Emerging markets businesses to deliver a double-digit growth from Q2 onwards, chairman says

** 9 analysts covering GLEN have a "buy" rating on average, median PT is 2,365 rupees - data compiled by LSEG

** Stock up ~25% YTD

($1 = 87.3675 Indian rupees)

(Reporting by Urvi Dugar)

(([email protected]))

Aug 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• APPROVES TRANSFER OF CONSUMER CARE BUSINESS TO SUBSIDIARY

• BUSINESS TRANSFER VALUED AT 2.40 BILLION RUPEES

Source text: ID:nBSE9HGC1t

Further company coverage: GLEN.NS

(([email protected];))

Corrects to add "treatment" in headline

July 11 (Reuters) - Shares of Glenmark Pharmaceuticals GLEN.NS jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie ABBV.N for its cancer treatment.

(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sonia Cheema)

(([email protected]; X: @MukherjeeHritam;))

July 10 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• ICHNOS GLENMARK INNOVATION (IGI) AND ABBVIE ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT

• LICENSING AGREEMENT FOR ISB 2001

• IGI WILL RECEIVE AN UPFRONT PAYMENT OF $700 MILLION, ELIGIBLE TO RECEIVE UP TO $1.225 BILLION

Source text: ID:nBSE3Lp8jW

Further company coverage: GLEN.NS

(([email protected];))

June 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• U.S. FDA INSPECTION AT THE COMPANY'S FACILITY AT MONROE, NORTH CAROLINA, USA

• COMPANY WAS ISSUED A FORM 483 WITH FIVE OBSERVATIONS BY USFDA

• OBSERVATIONS ARE PROCEDURAL IN NATURE

• THERE WAS NO OBSERVATION RELATED TO DATA INTEGRITY REPORTED

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];;))

June 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• TO LAUNCH DCGI-APPROVED ZANUBRUTINIB IN INDIA

• ZANUBRUTINIB TO BE MARKETED AS BRUKINSA IN INDIA

Source text: ID:nBSE95v3F3

Further company coverage: GLEN.NS

(([email protected];;))

May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.

Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.

Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.

Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.

The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.

Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.

The U.S. imports nearly a third of Indian pharma products sold overseas.

India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.

(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)

(([email protected]; 8800437922;))

May 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS LTD - IGI RECEIVES FDA FAST TRACK DESIGNATION FOR ISB 2001

Source text: ID:nBSE1SYXkx

Further company coverage: GLEN.NS

(([email protected];;))

April 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• CLAIRIFIES REPORT ABOUT CDSCO FLAGGING DRUGS

• PRODUCTS REFERRED TO IN REPORT SPURIOUS; NOT MADE BY CO

Source text: ID:nnAZN3RNEEN

Further company coverage: GLEN.NS

(([email protected];;))

April 16 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - GLENMARK PHARMACEUTICALS INC., USA TO LAUNCH DEXTROAMPHETAMINE SACCHARATE TABLETS

• GLENMARK PHARMA-GLENMARK PHARMA INC TO LAUNCH MIXED SALTS OF SINGLE ENTITY AMPHETAMINE PRODUCT TABLETS

Further company coverage: GLEN.NS

(([email protected];))

April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.

U.S. accounts for a third of India's overall pharma exports.

Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.

On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.

Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.

Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.

The pharma index has fallen 14.4% this year.

(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)

(([email protected];))

April 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC., USA LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 750 MG/VIAL, 1.25 G/VIAL AND 1.5 G/VIAL (SINGLE-DOSE VIAL)

Source text: ID:nPn4wYPFna

Further company coverage: GLEN.NS

(([email protected];))

March 27 - ** Shares of Glenmark Pharmaceuticals Ltd GLEN.NS rise 2.3% to 1,495.95 rupees
** Stock top gainer on Nifty Pharma .NIPHARM index, which is down 1%
** HSBC upgrades drugmaker to "buy" from "hold" citing visibility on margin expansion for its base business; raises PT to 1,785 rupees from 1,630 rupees
** Brokerage also sees scope for re-rating if GLEN secures a licensing deal for its targeted cancer therapy ISB 2001
** GLEN, like half the stocks on 20-member NIPHARM, is rated "buy" - data compiled by LSEG
** Stock trims YTD losses to ~7%, faring better than pharma stocks' nearly 10% drop this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

March 20 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS - RECEIVES FDA APPROVAL FOR OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Source text: ID:nBSE71jjXQ

Further company coverage: GLEN.NS

(([email protected];))

Feb 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC LAUNCHES EPINEPHRINE INJECTION USP MULTIPLE-DOSE VIAL

Source text: ID:nBSEtnRNn

Further company coverage: GLEN.NS

(([email protected];;))

** Shares of Glenmark Pharmaceuticals GLEN.NS up ~4% to 1350.5 rupees

** Co settles remaining antitrust and consumer protection lawsuits with three plaintiffs in connection with generic cholesterol drug Zetia

** Plaintiffs include Humana HUM.N, Centene Corp CNC.N

and Kaiser Foundation Health Plan [RIC:RIC:KISERF.UL]

** Under terms of $7 mln settlement, Glenmark denies allegations by plaintiffs, concedes no liability

** Including session's gains, GLEN shares up 48.3% in the last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Feb 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA Q3 CONSOL NET PROFIT 3.48 BILLION RUPEES

• GLENMARK PHARMA Q3 CONSOL NET SALES 33.02 BILLION RUPEES

Source text: ID:nBSE5683hc

Further company coverage: GLEN.NS

(([email protected];))

Feb 10 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• RECEIVES MHRA APPROVAL TO MARKET WINLEVI IN UK

• WINLEVI APPROVED FOR TREATMENT OF ACNE VULGARIS IN PATIENTS AGED 12+

Source text: ID:nBSE85XZy7

Further company coverage: GLEN.NS

(([email protected];;))

Jan 21 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS - LAUNCHES PHYTONADIONE INJECTABLE EMULSION USP

Source text: ID:nNSEJjlCj

Further company coverage: GLEN.NS

(([email protected];;))

Dec 16 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC., USA LAUNCHES LACOSAMIDE ORAL SOLUTION, 10 MG/ML

Source text: ID:nBSE28f2Ds

Further company coverage: GLEN.NS

(([email protected];;))

** Shares of Glenmark Pharmaceuticals GLEN.NS rise 2.6% to 1,554 rupees

** GLEN top gainer on Nifty Pharma index .NIPHARM, which is up 0.14%

** Ichnos Glenmark Innovation says early-stage results for its blood cancer drug, ISB 2001, showed promising results

** Ichnos Glenmark Innovation is a partnership between Ichnos Sciences and Glenmark Pharma to develop cancer treatments

** ISB 2001 developed for treating advanced multiple myeloma, a type of cancer developing in plasma cells

** 83% of 18 patients in study showed partial or complete response to treatment, with cancer going away completely in 20% - co

** Stock set to snap a four-day losing streak

** Analysts' avg rating on GLEN at "buy; median PT is 1,700 rupees - LSEG data

** Stock up ~55% YTD, while pharma index is up 33%

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Nov 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMACEUTICALS INC., USA LAUNCHES TRAVOPROST OPHTHALMIC SOLUTION

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];;))